Concepts (280)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Melanoma | 18 | 2024 | 5706 | 2.830 |
Why?
|
Skin Neoplasms | 17 | 2024 | 5863 | 2.090 |
Why?
|
Prurigo | 11 | 2023 | 26 | 2.070 |
Why?
|
Exanthema | 5 | 2024 | 503 | 1.570 |
Why?
|
Neoplasms | 23 | 2024 | 22371 | 1.430 |
Why?
|
Skin | 12 | 2024 | 4503 | 1.300 |
Why?
|
Psoriasis | 4 | 2022 | 926 | 1.290 |
Why?
|
Melanosis | 3 | 2024 | 93 | 1.180 |
Why?
|
Pruritus | 10 | 2022 | 379 | 1.160 |
Why?
|
Drug Eruptions | 5 | 2024 | 335 | 1.140 |
Why?
|
International Classification of Diseases | 3 | 2022 | 937 | 1.100 |
Why?
|
Hyperpigmentation | 3 | 2023 | 116 | 1.100 |
Why?
|
Skin Diseases | 5 | 2024 | 1085 | 0.860 |
Why?
|
Interferon Regulatory Factor-3 | 1 | 2024 | 146 | 0.840 |
Why?
|
Biological Products | 2 | 2021 | 948 | 0.770 |
Why?
|
Connective Tissue Diseases | 1 | 2024 | 285 | 0.750 |
Why?
|
Cochlear Implantation | 3 | 2017 | 317 | 0.720 |
Why?
|
Oncolytic Virotherapy | 2 | 2023 | 520 | 0.710 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 2 | 2020 | 210 | 0.710 |
Why?
|
Scalp Dermatoses | 1 | 2020 | 44 | 0.680 |
Why?
|
Paresthesia | 1 | 2020 | 160 | 0.650 |
Why?
|
Quinolines | 1 | 2024 | 772 | 0.620 |
Why?
|
Alopecia | 2 | 2020 | 416 | 0.610 |
Why?
|
Neurodermatitis | 3 | 2022 | 8 | 0.590 |
Why?
|
Retrospective Studies | 33 | 2024 | 81762 | 0.540 |
Why?
|
Antimalarials | 1 | 2023 | 909 | 0.540 |
Why?
|
Hearing Loss, Sensorineural | 2 | 2013 | 783 | 0.540 |
Why?
|
Cohort Studies | 18 | 2024 | 41754 | 0.530 |
Why?
|
Pemphigoid, Bullous | 3 | 2022 | 110 | 0.530 |
Why?
|
Arthritis, Psoriatic | 1 | 2019 | 219 | 0.510 |
Why?
|
Vestibular Diseases | 2 | 2015 | 232 | 0.500 |
Why?
|
Administration, Cutaneous | 5 | 2023 | 716 | 0.490 |
Why?
|
Humans | 107 | 2024 | 768166 | 0.490 |
Why?
|
Rheumatic Diseases | 1 | 2022 | 659 | 0.480 |
Why?
|
Quality-Adjusted Life Years | 5 | 2020 | 1741 | 0.470 |
Why?
|
Immunosuppressive Agents | 3 | 2024 | 4206 | 0.470 |
Why?
|
Mycosis Fungoides | 3 | 2021 | 169 | 0.460 |
Why?
|
Autoimmune Diseases | 2 | 2024 | 2257 | 0.440 |
Why?
|
Immunotherapy | 13 | 2024 | 4755 | 0.430 |
Why?
|
Patient Admission | 1 | 2021 | 1365 | 0.430 |
Why?
|
Auditory Diseases, Central | 1 | 2012 | 6 | 0.420 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2540 | 0.400 |
Why?
|
Cochlear Implants | 2 | 2017 | 342 | 0.400 |
Why?
|
Antirheumatic Agents | 1 | 2022 | 1381 | 0.390 |
Why?
|
Acne Vulgaris | 3 | 2023 | 352 | 0.390 |
Why?
|
Hearing Loss | 1 | 2019 | 785 | 0.380 |
Why?
|
Pneumonia, Aspiration | 1 | 2012 | 145 | 0.370 |
Why?
|
Tumor Microenvironment | 1 | 2024 | 3948 | 0.360 |
Why?
|
Quality of Life | 12 | 2023 | 13490 | 0.350 |
Why?
|
Seasons | 4 | 2023 | 1524 | 0.340 |
Why?
|
Software | 1 | 2024 | 4478 | 0.340 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2024 | 3251 | 0.320 |
Why?
|
Search Engine | 3 | 2020 | 142 | 0.320 |
Why?
|
Pneumonia, Ventilator-Associated | 1 | 2012 | 278 | 0.310 |
Why?
|
Cognition Disorders | 3 | 2019 | 3980 | 0.290 |
Why?
|
Nutrition Surveys | 4 | 2022 | 1738 | 0.290 |
Why?
|
Acoustic Stimulation | 1 | 2012 | 1255 | 0.290 |
Why?
|
Dermatology | 3 | 2022 | 905 | 0.280 |
Why?
|
Cross-Sectional Studies | 18 | 2022 | 26379 | 0.280 |
Why?
|
Hospital Costs | 2 | 2012 | 957 | 0.280 |
Why?
|
Pancreatic Neoplasms | 1 | 2024 | 5446 | 0.260 |
Why?
|
United States | 22 | 2024 | 73039 | 0.260 |
Why?
|
Vertigo | 2 | 2019 | 205 | 0.260 |
Why?
|
Male | 41 | 2024 | 364719 | 0.250 |
Why?
|
Aged | 27 | 2024 | 171504 | 0.250 |
Why?
|
Female | 43 | 2024 | 397192 | 0.250 |
Why?
|
Mevalonic Acid | 1 | 2024 | 46 | 0.230 |
Why?
|
Middle Aged | 29 | 2024 | 223492 | 0.220 |
Why?
|
Toll-Like Receptor 3 | 1 | 2024 | 99 | 0.220 |
Why?
|
Vestibule, Labyrinth | 2 | 2016 | 235 | 0.220 |
Why?
|
Head and Neck Neoplasms | 3 | 2013 | 2931 | 0.220 |
Why?
|
Scleroderma, Localized | 1 | 2023 | 85 | 0.210 |
Why?
|
Erythema Multiforme | 1 | 2022 | 31 | 0.200 |
Why?
|
Adult | 26 | 2024 | 223646 | 0.200 |
Why?
|
Cost of Illness | 3 | 2021 | 1951 | 0.190 |
Why?
|
Pyridoxine | 1 | 2022 | 108 | 0.190 |
Why?
|
Pancreatitis, Chronic | 1 | 2024 | 282 | 0.190 |
Why?
|
Dermatitis | 1 | 2023 | 203 | 0.190 |
Why?
|
Vitiligo | 1 | 2022 | 97 | 0.180 |
Why?
|
Germ Cells | 2 | 2022 | 644 | 0.180 |
Why?
|
Signal Transduction | 1 | 2024 | 23645 | 0.180 |
Why?
|
Antineoplastic Agents | 1 | 2024 | 13676 | 0.180 |
Why?
|
Health Care Costs | 2 | 2013 | 3239 | 0.180 |
Why?
|
Respiration, Artificial | 1 | 2012 | 2726 | 0.180 |
Why?
|
Toll-Like Receptor 4 | 1 | 2024 | 588 | 0.180 |
Why?
|
Incidence | 7 | 2024 | 21538 | 0.180 |
Why?
|
Lung Neoplasms | 2 | 2022 | 13586 | 0.180 |
Why?
|
Facial Neoplasms | 1 | 2021 | 126 | 0.170 |
Why?
|
Biological Factors | 1 | 2021 | 156 | 0.170 |
Why?
|
Warts | 1 | 2020 | 66 | 0.170 |
Why?
|
Massachusetts | 3 | 2021 | 8890 | 0.170 |
Why?
|
Comorbidity | 6 | 2022 | 10590 | 0.170 |
Why?
|
Stevens-Johnson Syndrome | 1 | 2022 | 232 | 0.170 |
Why?
|
Eczema | 1 | 2022 | 245 | 0.170 |
Why?
|
Antibodies, Monoclonal | 4 | 2023 | 9263 | 0.160 |
Why?
|
Hydroxychloroquine | 1 | 2023 | 426 | 0.160 |
Why?
|
Sezary Syndrome | 1 | 2020 | 80 | 0.160 |
Why?
|
Skin Pigmentation | 1 | 2021 | 280 | 0.160 |
Why?
|
SEER Program | 1 | 2024 | 1444 | 0.160 |
Why?
|
Databases, Factual | 4 | 2024 | 8080 | 0.160 |
Why?
|
Information Seeking Behavior | 1 | 2020 | 116 | 0.160 |
Why?
|
Mohs Surgery | 1 | 2021 | 217 | 0.160 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2023 | 737 | 0.160 |
Why?
|
Adjuvants, Immunologic | 1 | 2024 | 998 | 0.160 |
Why?
|
Cost-Benefit Analysis | 5 | 2017 | 5536 | 0.150 |
Why?
|
Risk Factors | 9 | 2024 | 74944 | 0.150 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2024 | 2059 | 0.140 |
Why?
|
Canada | 2 | 2020 | 2130 | 0.140 |
Why?
|
Renin-Angiotensin System | 1 | 2022 | 737 | 0.140 |
Why?
|
Lymph Node Excision | 1 | 2023 | 1271 | 0.140 |
Why?
|
Prevalence | 5 | 2020 | 15869 | 0.130 |
Why?
|
Risk Assessment | 5 | 2024 | 24315 | 0.130 |
Why?
|
Carcinoma, Basal Cell | 1 | 2021 | 565 | 0.130 |
Why?
|
Cholesteatoma, Middle Ear | 1 | 2015 | 52 | 0.120 |
Why?
|
Tympanoplasty | 1 | 2015 | 73 | 0.120 |
Why?
|
Mastoid | 1 | 2015 | 100 | 0.120 |
Why?
|
Educational Status | 2 | 2013 | 2515 | 0.120 |
Why?
|
Logistic Models | 4 | 2019 | 13290 | 0.120 |
Why?
|
Ligands | 1 | 2022 | 3284 | 0.120 |
Why?
|
Computational Biology | 2 | 2024 | 3568 | 0.120 |
Why?
|
Hodgkin Disease | 1 | 2022 | 1384 | 0.120 |
Why?
|
Dermatitis, Atopic | 1 | 2022 | 737 | 0.120 |
Why?
|
Dermatologic Agents | 1 | 2017 | 313 | 0.110 |
Why?
|
Otitis Media | 1 | 2015 | 288 | 0.110 |
Why?
|
Neck Pain | 1 | 2014 | 191 | 0.100 |
Why?
|
Inpatients | 2 | 2021 | 2566 | 0.100 |
Why?
|
Tetracycline | 2 | 2023 | 216 | 0.100 |
Why?
|
Hospital Charges | 1 | 2014 | 347 | 0.100 |
Why?
|
Space Perception | 1 | 2015 | 466 | 0.100 |
Why?
|
Urinary Catheterization | 1 | 2013 | 195 | 0.100 |
Why?
|
Minocycline | 2 | 2023 | 170 | 0.100 |
Why?
|
Maryland | 1 | 2012 | 278 | 0.100 |
Why?
|
Lymph Nodes | 1 | 2023 | 3474 | 0.100 |
Why?
|
Baltimore | 3 | 2018 | 233 | 0.090 |
Why?
|
Confidence Intervals | 2 | 2018 | 2923 | 0.090 |
Why?
|
Language Development | 1 | 2012 | 183 | 0.090 |
Why?
|
Neck Dissection | 1 | 2012 | 201 | 0.090 |
Why?
|
Developmental Disabilities | 1 | 2019 | 1518 | 0.090 |
Why?
|
Antiviral Agents | 1 | 2023 | 3073 | 0.090 |
Why?
|
Treatment Outcome | 11 | 2021 | 65371 | 0.090 |
Why?
|
Drug Approval | 1 | 2018 | 821 | 0.090 |
Why?
|
Postural Balance | 1 | 2015 | 639 | 0.090 |
Why?
|
Cochlear Nerve | 1 | 2012 | 202 | 0.090 |
Why?
|
Hepatectomy | 1 | 2014 | 588 | 0.090 |
Why?
|
Sequence Analysis, DNA | 1 | 2021 | 4786 | 0.090 |
Why?
|
Pneumonia | 1 | 2022 | 2163 | 0.090 |
Why?
|
Hematologic Neoplasms | 1 | 2022 | 1907 | 0.090 |
Why?
|
Accidental Falls | 2 | 2015 | 1080 | 0.090 |
Why?
|
Patient Acceptance of Health Care | 2 | 2021 | 3231 | 0.090 |
Why?
|
Diagnostic Imaging | 1 | 2024 | 3533 | 0.090 |
Why?
|
Socioeconomic Factors | 2 | 2021 | 7852 | 0.080 |
Why?
|
Catheter-Related Infections | 1 | 2013 | 275 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2665 | 0.080 |
Why?
|
Vaccination | 1 | 2022 | 3437 | 0.080 |
Why?
|
Steroids | 1 | 2014 | 938 | 0.080 |
Why?
|
Colectomy | 1 | 2014 | 696 | 0.080 |
Why?
|
Mice, Knockout | 1 | 2024 | 14488 | 0.080 |
Why?
|
Self Report | 1 | 2020 | 3773 | 0.080 |
Why?
|
Internet | 2 | 2018 | 3110 | 0.070 |
Why?
|
Odds Ratio | 3 | 2018 | 9669 | 0.070 |
Why?
|
Pain | 2 | 2020 | 5100 | 0.070 |
Why?
|
Healthcare Disparities | 2 | 2021 | 3415 | 0.070 |
Why?
|
Visual Perception | 1 | 2015 | 1402 | 0.070 |
Why?
|
Aging | 2 | 2016 | 8744 | 0.070 |
Why?
|
Urinary Tract Infections | 1 | 2013 | 804 | 0.070 |
Why?
|
Academic Medical Centers | 2 | 2018 | 2784 | 0.070 |
Why?
|
Genome-Wide Association Study | 2 | 2022 | 12795 | 0.070 |
Why?
|
Activities of Daily Living | 1 | 2015 | 2430 | 0.060 |
Why?
|
Cluster Analysis | 2 | 2024 | 2732 | 0.060 |
Why?
|
Postoperative Care | 1 | 2012 | 1480 | 0.060 |
Why?
|
Vestibular Function Tests | 2 | 2016 | 128 | 0.060 |
Why?
|
Mice, Inbred C57BL | 1 | 2024 | 22379 | 0.060 |
Why?
|
Age of Onset | 1 | 2012 | 3347 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2023 | 9419 | 0.060 |
Why?
|
Chronic Disease | 4 | 2022 | 9384 | 0.060 |
Why?
|
Delivery of Health Care | 1 | 2023 | 5367 | 0.060 |
Why?
|
Time Factors | 3 | 2024 | 40218 | 0.060 |
Why?
|
Cost Savings | 2 | 2024 | 904 | 0.060 |
Why?
|
Inflammation | 1 | 2024 | 10873 | 0.060 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2019 | 3729 | 0.060 |
Why?
|
Hospital Mortality | 3 | 2013 | 5349 | 0.060 |
Why?
|
Radioimmunotherapy | 1 | 2024 | 93 | 0.060 |
Why?
|
Physicians | 1 | 2022 | 4598 | 0.060 |
Why?
|
Photogrammetry | 1 | 2023 | 77 | 0.050 |
Why?
|
Longitudinal Studies | 3 | 2016 | 14783 | 0.050 |
Why?
|
Health Status | 2 | 2014 | 4091 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5432 | 0.050 |
Why?
|
Neoplasm Staging | 1 | 2018 | 11244 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 2 | 2023 | 18065 | 0.050 |
Why?
|
Pandemics | 1 | 2023 | 8748 | 0.050 |
Why?
|
Case-Control Studies | 4 | 2024 | 22291 | 0.050 |
Why?
|
Bone Density | 1 | 2016 | 3573 | 0.050 |
Why?
|
Mortality | 2 | 2024 | 2911 | 0.050 |
Why?
|
Venous Thrombosis | 1 | 2012 | 1323 | 0.050 |
Why?
|
Aged, 80 and over | 6 | 2021 | 59629 | 0.050 |
Why?
|
Child, Preschool | 3 | 2019 | 42669 | 0.050 |
Why?
|
Lactate Dehydrogenases | 1 | 2022 | 26 | 0.050 |
Why?
|
Interleukin-7 | 1 | 2022 | 146 | 0.050 |
Why?
|
Administration, Topical | 1 | 2024 | 703 | 0.050 |
Why?
|
Multivariate Analysis | 2 | 2012 | 12077 | 0.050 |
Why?
|
Religion and Sex | 1 | 2021 | 2 | 0.050 |
Why?
|
Doxycycline | 1 | 2023 | 349 | 0.050 |
Why?
|
Survival Rate | 2 | 2012 | 12840 | 0.050 |
Why?
|
Biological Therapy | 1 | 2022 | 140 | 0.050 |
Why?
|
Vitamin B 6 | 1 | 2022 | 237 | 0.050 |
Why?
|
Surgical Procedures, Operative | 1 | 2012 | 1932 | 0.040 |
Why?
|
Catheter Ablation | 1 | 2014 | 2780 | 0.040 |
Why?
|
Age Factors | 2 | 2018 | 18412 | 0.040 |
Why?
|
Australia | 1 | 2024 | 1265 | 0.040 |
Why?
|
Tacrolimus | 1 | 2024 | 750 | 0.040 |
Why?
|
Adolescent | 7 | 2024 | 89169 | 0.040 |
Why?
|
Prospective Studies | 4 | 2023 | 54926 | 0.040 |
Why?
|
Severity of Illness Index | 2 | 2018 | 15948 | 0.040 |
Why?
|
Liver Neoplasms | 1 | 2014 | 4362 | 0.040 |
Why?
|
Health Surveys | 2 | 2020 | 4057 | 0.040 |
Why?
|
Mice | 1 | 2024 | 82029 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2023 | 1105 | 0.030 |
Why?
|
Isotretinoin | 1 | 2017 | 134 | 0.030 |
Why?
|
Drug Costs | 1 | 2024 | 1195 | 0.030 |
Why?
|
Delayed Diagnosis | 1 | 2019 | 467 | 0.030 |
Why?
|
Length of Stay | 3 | 2014 | 6498 | 0.030 |
Why?
|
Mental Disorders | 1 | 2015 | 6874 | 0.030 |
Why?
|
Nortriptyline | 1 | 2014 | 79 | 0.030 |
Why?
|
Drug Prescriptions | 1 | 2024 | 1668 | 0.030 |
Why?
|
Gene Frequency | 1 | 2021 | 3623 | 0.030 |
Why?
|
Anti-Bacterial Agents | 2 | 2023 | 7477 | 0.030 |
Why?
|
Colorectal Neoplasms | 1 | 2014 | 6974 | 0.030 |
Why?
|
Child | 3 | 2023 | 80917 | 0.030 |
Why?
|
Consensus | 1 | 2024 | 3212 | 0.030 |
Why?
|
Cyclohexanecarboxylic Acids | 1 | 2014 | 139 | 0.030 |
Why?
|
Vitamins | 1 | 2022 | 1638 | 0.030 |
Why?
|
Phenotype | 2 | 2022 | 16726 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2024 | 4912 | 0.030 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2018 | 465 | 0.030 |
Why?
|
Postoperative Complications | 2 | 2013 | 15832 | 0.030 |
Why?
|
Neoplasm Invasiveness | 1 | 2021 | 3620 | 0.030 |
Why?
|
Amines | 1 | 2014 | 280 | 0.030 |
Why?
|
Young Adult | 4 | 2024 | 60066 | 0.030 |
Why?
|
Injections, Epidural | 1 | 2014 | 203 | 0.030 |
Why?
|
Confusion | 1 | 2015 | 278 | 0.030 |
Why?
|
DNA Copy Number Variations | 1 | 2021 | 2048 | 0.030 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2018 | 1338 | 0.030 |
Why?
|
Antidepressive Agents, Tricyclic | 1 | 2014 | 430 | 0.030 |
Why?
|
Animals | 1 | 2024 | 169246 | 0.020 |
Why?
|
Infant | 1 | 2013 | 36535 | 0.020 |
Why?
|
Physical Therapy Modalities | 1 | 2014 | 533 | 0.020 |
Why?
|
Reference Values | 1 | 2018 | 4938 | 0.020 |
Why?
|
Mitochondria | 1 | 2024 | 3681 | 0.020 |
Why?
|
Alleles | 1 | 2021 | 6894 | 0.020 |
Why?
|
Imaging, Three-Dimensional | 1 | 2023 | 4063 | 0.020 |
Why?
|
Temperature | 1 | 2017 | 2234 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2017 | 2434 | 0.020 |
Why?
|
Drainage | 1 | 2015 | 1183 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2018 | 1673 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 3671 | 0.020 |
Why?
|
Vitamin D | 1 | 2022 | 3311 | 0.020 |
Why?
|
Mutation | 2 | 2024 | 30238 | 0.020 |
Why?
|
Cervical Vertebrae | 1 | 2014 | 979 | 0.020 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2014 | 1141 | 0.020 |
Why?
|
Prognosis | 2 | 2019 | 30010 | 0.020 |
Why?
|
Memory Disorders | 1 | 2015 | 1200 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2018 | 2118 | 0.020 |
Why?
|
Analgesics | 1 | 2014 | 1071 | 0.020 |
Why?
|
Genotype | 1 | 2021 | 13045 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2023 | 5703 | 0.020 |
Why?
|
Regression Analysis | 1 | 2016 | 6340 | 0.020 |
Why?
|
Disease Progression | 1 | 2023 | 13671 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2023 | 20227 | 0.020 |
Why?
|
Cognition | 1 | 2022 | 7073 | 0.020 |
Why?
|
Pain Measurement | 1 | 2014 | 3583 | 0.010 |
Why?
|
Sex Factors | 1 | 2018 | 10632 | 0.010 |
Why?
|
Anxiety Disorders | 1 | 2015 | 2748 | 0.010 |
Why?
|
Medicare | 1 | 2022 | 6809 | 0.010 |
Why?
|
Depressive Disorder | 1 | 2015 | 3721 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2021 | 16045 | 0.010 |
Why?
|
Research Design | 1 | 2018 | 6211 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2018 | 8054 | 0.010 |
Why?
|
Hospitalization | 1 | 2021 | 10840 | 0.010 |
Why?
|
Pulmonary Embolism | 1 | 2012 | 2599 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2014 | 39348 | 0.010 |
Why?
|
Concepts
(280)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(99)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_